November 18, 2016 - By Darrin Black · 0 Comments
The stock of Veracyte Incorporated (NASDAQ:VCYT) registered a decrease of 0.5% in short interest. VCYT’s total short interest was 1.25 million shares in November as published by FINRA. Its down 0.5% from 1.25M shares, reported previously. With 95,000 shares average volume, it will take short sellers 13 days to cover their VCYT’s short positions. The short interest to Veracyte Incorporated’s float is 8.78%. About 103,497 shares traded hands. Veracyte Inc (NASDAQ:VCYT) has risen 33.63% since April 18, 2016 and is uptrending. It has outperformed by 29.20% the S&P500.
Veracyte, Inc. is a molecular diagnostics company. The company has a market cap of $257.54 million. The Firm is engaged in developing and delivering genomic solutions that resolve diagnostic ambiguity and enable physicians to make informed treatment decisions at an early-stage in patient care. It currently has negative earnings. The Firm targets diseases in which various patients undergo diagnostic procedures that could be avoided with diagnosis from a cytology sample taken preoperatively.
Insitutional Activity: The institutional sentiment increased to 2 in Q2 2016. Its up 0.59, from 1.41 in 2016Q1. The ratio is positive, as 3 funds sold all Veracyte Inc shares owned while 14 reduced positions. 6 funds bought stakes while 18 increased positions. They now own 15.02 million shares or 1.37% less from 15.23 million shares in 2016Q1.
Moreover, State Common Retirement Fund has 0% invested in Veracyte Inc (NASDAQ:VCYT) for 12,300 shares. Schwab Charles Invest Management Incorporated has invested 0% of its portfolio in Veracyte Inc (NASDAQ:VCYT). Vanguard Group accumulated 526,438 shares or 0% of the stock. Spark Invest Management Limited Liability reported 59,100 shares or 0.03% of all its holdings. The Illinois-based Northern Tru has invested 0% in Veracyte Inc (NASDAQ:VCYT). Blackrock Advsr Ltd has 3,684 shares for 0% of their US portfolio. Panagora Asset Incorporated holds 0% or 2,264 shares in its portfolio. Teachers Advisors holds 17,773 shares or 0% of its portfolio. Eventide Asset Management Ltd accumulated 2.25 million shares or 0.69% of the stock. Spot Trading Ltd Liability Corporation accumulated 15,900 shares or 0% of the stock. Strs Ohio last reported 0% of its portfolio in the stock. Nationwide Fund Advisors holds 8,588 shares or 0% of its portfolio. Bridgeway Mgmt Inc has invested 0.01% of its portfolio in Veracyte Inc (NASDAQ:VCYT). Clough Capital Prtn Lp holds 267,547 shares or 0.07% of its portfolio. Susquehanna Intll Grp Incorporated Ltd Liability Partnership last reported 35,707 shares in the company.
Insider Transactions: Since May 31, 2016, the stock had 2 buys, and 0 insider sales for $54,267 net activity. Anderson Bonnie H also bought $27,286 worth of Veracyte Inc (NASDAQ:VCYT) on Tuesday, May 31.
Out of 3 analysts covering Veracyte (NASDAQ:VCYT), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Veracyte has been the topic of 5 analyst reports since August 14, 2015 according to StockzIntelligence Inc. The stock of Veracyte Inc (NASDAQ:VCYT) earned “Overweight” rating by Piper Jaffray on Friday, August 14. The stock of Veracyte Inc (NASDAQ:VCYT) earned “Buy” rating by Cantor Fitzgerald on Friday, December 18. The stock of Veracyte Inc (NASDAQ:VCYT) earned “Buy” rating by BTIG Research on Friday, August 14.
Veracyte, Inc., incorporated on August 15, 2006, is a molecular diagnostics company. The Firm is engaged in developing and delivering genomic solutions that resolve diagnostic ambiguity and enable physicians to make informed treatment decisions at an early-stage in patient care. The Firm targets diseases in which various patients undergo diagnostic procedures that could be avoided with diagnosis from a cytology sample taken preoperatively. The Company’s activities are based in South San Francisco, California and Austin, Texas, and it operates in the United States.
More recent Veracyte Inc (NASDAQ:VCYT) news were published by: Prnewswire.com which released: “Veracyte Announces Pricing of Public Offering of 5000000 Shares of Common Stock” on November 02, 2016. Also Quotes.Wsj.com published the news titled: “Veracyte Inc. VCYT (US: Nasdaq)” on October 26, 2013. Reuters.com‘s news article titled: “BRIEF-Broadfin Capital Llc reports 5.8 pct passive stake in Veracyte Inc” with publication date: November 04, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Darrin Black